158 related articles for article (PubMed ID: 9717065)
1. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study.
Goldbourt U; Brunner D; Behar S; Reicher-Reiss H
Eur Heart J; 1998 Jul; 19 Suppl H():H42-7. PubMed ID: 9717065
[TBL] [Abstract][Full Text] [Related]
2. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
3. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress.
Ericsson CG
Eur Heart J; 1998 Jul; 19 Suppl H():H37-41. PubMed ID: 9717064
[TBL] [Abstract][Full Text] [Related]
4. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
Arcavi L; Behar S; Caspi A; Reshef N; Boyko V; Knobler H
Am Heart J; 2004 Feb; 147(2):239-45. PubMed ID: 14760320
[TBL] [Abstract][Full Text] [Related]
5. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial.
Goldenberg I; Boyko V; Tennenbaum A; Tanne D; Behar S; Guetta V
Arch Intern Med; 2009 Mar; 169(5):508-14. PubMed ID: 19273782
[TBL] [Abstract][Full Text] [Related]
6. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.
Tenenbaum A; Motro M; Fisman EZ; Tanne D; Boyko V; Behar S
Arch Intern Med; 2005 May; 165(10):1154-60. PubMed ID: 15911729
[TBL] [Abstract][Full Text] [Related]
7. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).
Goldenberg I; Goldbourt U; Boyko V; Behar S; Reicher-Reiss H;
Am J Cardiol; 2006 Feb; 97(4):466-71. PubMed ID: 16461038
[TBL] [Abstract][Full Text] [Related]
8. Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
de Faire U; Ericsson CG; Hamsten A; Nilsson J
Drugs Exp Clin Res; 1995; 21(3):105-24. PubMed ID: 7555614
[TBL] [Abstract][Full Text] [Related]
9. Effects of bezafibrate on HDL2/HDL3 ratio in postmenopausal hypertriglyceridemic women.
Ushiroyama T; Sakuma K; Nosaka S
J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):142-8. PubMed ID: 16891292
[TBL] [Abstract][Full Text] [Related]
10. [Fibrates in the secondary prevention of ischemic cardiopathy].
Posadas Romero C
Arch Cardiol Mex; 2001; 71 Suppl 1():S139-41. PubMed ID: 11565320
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia.
Schumacher M; Eber B; Silberbauer K; Breier C; Stühlinger W; Schmidt P; Gaul G; Klein W
Acta Med Austriaca; 1992; 19(5):140-4. PubMed ID: 1298143
[TBL] [Abstract][Full Text] [Related]
12. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia.
Kehely A; MacMahon M; Barbir M; Wray R; Hunt BJ; Prescott RJ; Thompson GR
QJM; 1995 Jun; 88(6):421-7. PubMed ID: 7648234
[TBL] [Abstract][Full Text] [Related]
13. Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort.
Clearfield MB; Weis SE; Willis JM; Vasenius KA; McConathy WJ
J Am Osteopath Assoc; 2002 Jul; 102(7):377-84. PubMed ID: 12138952
[TBL] [Abstract][Full Text] [Related]
14. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial.
Goldenberg I; Benderly M; Goldbourt U;
J Am Coll Cardiol; 2008 Jan; 51(4):459-65. PubMed ID: 18222357
[TBL] [Abstract][Full Text] [Related]
15. Prevention of restenosis by bezafibrate after successful coronary angioplasty.
Ishiwata S; Nakanishi S; Nishiyama S; Seki A
Coron Artery Dis; 1995 Nov; 6(11):883-9. PubMed ID: 8696533
[TBL] [Abstract][Full Text] [Related]
16. Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
Brodov Y; Behar S; Boyko V; Chouraqui P
Am J Cardiol; 2010 Dec; 106(12):1717-20. PubMed ID: 21126615
[TBL] [Abstract][Full Text] [Related]
17. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
[TBL] [Abstract][Full Text] [Related]
18. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
[TBL] [Abstract][Full Text] [Related]
19. [Effect of bezafibrate in isolated hypercholesterolemia and mixed hyperlipidemia on infarct risk (Stepwise Program for Individual Risk Identification and Therapy): an open multicenter study].
Sinzinger H; Virgolini I; Kudlacek P
Wien Klin Wochenschr; 1991; 103(13):381-7. PubMed ID: 1897230
[TBL] [Abstract][Full Text] [Related]
20. [Effects of bezafibrate in the diet of hypertensive patients with dyslipidemia and hyperfibrinogenemia].
Vázquez-Chávez C; Salinas-Orozco S; Gómez-Díaz RA; Rosso-Juárez MM; Moreno-Vázquez K; Nissen-Torres T; Argüero-Sánchez R
Rev Invest Clin; 1998; 50(6):491-6. PubMed ID: 10070221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
